TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review

Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Komal, Asma, Noreen, Mamoona, El-Kott, Attalla F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213534/
https://www.ncbi.nlm.nih.gov/pubmed/34145551
http://dx.doi.org/10.1007/s12026-021-09203-6
Descripción
Sumario:Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitumor properties are relatively diverse. In this review, three widely studied agonists RGC100, ARNAX, and poly-IC are discussed along with their structural and physiochemical differences including the signaling cascades through which they exert their actions. Comparison has been made to identify the finest agonist with maximum effectivity and the least side effect profile.

Ejemplares similares